FDA’s uniQure, REGENXBIO reversals could bolster other near-term rare disease applications
BioSpace
The FDA's recently altered outlook on the evidence required for approval of rare disease drugs could have immediate benefits for companies including Skyhawk Therapeutics, Capricor Therapeutics and Bio
pharminent
June 25, 2026 (Last updated: June 29, 2026)
BioSpace
The FDA’s recently altered outlook on the evidence required for approval of rare disease drugs could have immediate benefits for companies including Skyhawk Therapeutics, Capricor Therapeutics and Bio
